DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has recently introduced an enhanced gamma detection control unit, the Neoprobe® GDS (Model 2300), in connection with the Company’s marketing partner, Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company). The Neoprobe GDS control unit contains internal circuitry that enables it to communicate with Neoprobe’s family of wireless probes without the necessity of an external adapter. Neoprobe’s wireless gamma detection products are based on Bluetooth® technology and eliminate cumbersome cables that can unnecessarily complicate the surgical field. Neoprobe’s wireless probes are available with either straight or angled tips and can also be used with all previous models of the Company’s neo2000® control unit (Models 2000, 2100 and 2200) using an external serial port adapter. Neoprobe’s gamma detection products are widely used by cancer surgeons in a procedure called Sentinel Lymph Node Biopsy (SLNB) or Intraoperative Lymphatic Mapping (ILM).
